186 related articles for article (PubMed ID: 16610363)
1. Chaperoning oncogenes: Hsp90 as a target of geldanamycin.
Neckers L
Handb Exp Pharmacol; 2006; (172):259-77. PubMed ID: 16610363
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein 90.
Neckers L; Ivy SP
Curr Opin Oncol; 2003 Nov; 15(6):419-24. PubMed ID: 14624223
[TBL] [Abstract][Full Text] [Related]
3. Hsp90 inhibitors as novel cancer chemotherapeutic agents.
Neckers L
Trends Mol Med; 2002; 8(4 Suppl):S55-61. PubMed ID: 11927289
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein 90: the cancer chaperone.
Neckers L
J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
[TBL] [Abstract][Full Text] [Related]
5. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
Neckers L
Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
[TBL] [Abstract][Full Text] [Related]
6. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
Miyata Y
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
[TBL] [Abstract][Full Text] [Related]
7. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Miyata Y
Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
[TBL] [Abstract][Full Text] [Related]
8. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors.
Ibrahim NO; Hahn T; Franke C; Stiehl DP; Wirthner R; Wenger RH; Katschinski DM
Cancer Res; 2005 Dec; 65(23):11094-100. PubMed ID: 16322259
[TBL] [Abstract][Full Text] [Related]
9. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity.
Neckers L; Schulte TW; Mimnaugh E
Invest New Drugs; 1999; 17(4):361-73. PubMed ID: 10759403
[TBL] [Abstract][Full Text] [Related]
10. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
Neckers L
Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
[TBL] [Abstract][Full Text] [Related]
11. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents.
Neckers L; Neckers K
Expert Opin Emerg Drugs; 2002 Oct; 7(2):277-88. PubMed ID: 15989551
[TBL] [Abstract][Full Text] [Related]
12. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
13. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.
Castro JE; Prada CE; Loria O; Kamal A; Chen L; Burrows FJ; Kipps TJ
Blood; 2005 Oct; 106(7):2506-12. PubMed ID: 15972449
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 90 is a rational molecular target in breast cancer.
Neckers L
Breast Dis; 2002; 15():53-60. PubMed ID: 15687645
[TBL] [Abstract][Full Text] [Related]
15. [Hsp90: how a chaperone becomes a pharmacological target].
Jacquemin-Sablon A
Bull Cancer; 2003 Nov; 90(11):935-6. PubMed ID: 14706894
[No Abstract] [Full Text] [Related]
16. [Advances in antitumor activity of the hsp90 inhibitor geldanamycin].
Liao ZY; Zhen YS
Yao Xue Xue Bao; 2001 Sep; 36(9):716-20. PubMed ID: 12580116
[No Abstract] [Full Text] [Related]
17. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation.
Yun BG; Matts RL
Exp Cell Res; 2005 Jul; 307(1):212-23. PubMed ID: 15922741
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
[TBL] [Abstract][Full Text] [Related]
19. Analysis of hypoxia-inducible factor-1alpha accumulation and cell cycle in geldanamycin-treated human cervical carcinoma cells by laser scanning cytometry.
Schwock J; Geddie WR; Hedley DW
Cytometry A; 2005 Dec; 68(2):59-70. PubMed ID: 16228978
[TBL] [Abstract][Full Text] [Related]
20. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs.
Blagosklonny MV
Leukemia; 2002 Apr; 16(4):455-62. PubMed ID: 11960322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
